Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Oslo University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TG01 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Oslo University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TG01 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 06, 2022
Details : ONCOS-102 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 30, 2022
Lead Product(s) : Apricoxib,QS-21 Stimulon
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Agenus
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 07, 2022
Lead Product(s) : Apricoxib,QS-21 Stimulon
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Agenus
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Innovation Norway
Deal Size : $0.9 million
Deal Type : Funding
Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine
Details : With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Innovation Norway
Deal Size : $0.9 million
Deal Type : Funding
Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Targovax Granted European Patent for ONCOS-102 in Combination with Chemotherapy
Details : The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma. ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune sys...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONCOS-102,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Grants Fast Track Status To Targovax ONCOS-102 to Treat Refractory Advanced Melanoma
Details : The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 24, 2021
Lead Product(s) : ONCOS-102,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Targovax Releases Presentations of ONCOS-102 Mesothelioma 24-Month Data
Details : ONCOS-102, an immune activators used in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma clearly shown tumor responses and survival outcomes.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 14, 2021
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Targovax’s ONCOS-102 Mesothelioma 24-month Data Shows Class-leading Median Overall Survival
Details : The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (or later) line MPM to assess safety, immune activation and clinical efficacy compared with SoC alone.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Theradex Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Continued Survival Benefit in Targovax’s ONCOS-102 Trial in Mesothelioma at the 21-Month Follow-Up
Details : The trial is an open label, exploratory phase I/II trial adding ONCOS-102 to standard of care (SoC) chemotherapy (pemetrexed/cisplatin) in first and second (and later) line MPM to assess safety, immune activation and clinical efficacy vs SoC only.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
February 23, 2021
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Theradex Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable